21 – 30 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.
(
- Contribution to journal › Article
- 2008
-
Mark
Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy.
(
- Contribution to journal › Article
- 2007
-
Mark
2-deoxy-2-[F-18]fluoro-D-glucose uptake and correlation to intratumoral heterogeneity
(
- Contribution to journal › Article
- 2006
-
Mark
Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays
(
- Contribution to journal › Article
-
Mark
Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma.
(
- Contribution to journal › Article
-
Mark
p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
(
- Contribution to journal › Article
- 2004
-
Mark
DNA ploidy, S-phase fraction and associations with 2-18F-fluoro-deoxy-2-D-glucose positron emission tomography findings before and during therapy of head and neck squamous cell carcinoma.
(
- Contribution to journal › Article
- 2002
-
Mark
FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.
(
- Contribution to journal › Article
- 2001
-
Mark
Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas
(
- Contribution to journal › Article
- 1995
-
Mark
Radiation effects on S-phase duration, labelling index, potential doubling time and DNA distribution in head and neck cancer xenografts
(
- Contribution to journal › Article